ADispell’s Technology

Laboratory work using novel cellular research techniques has revealed a better understanding of how neurons communicate with each other in the brain and how to maintain their health. This neuron communication, which involves chemical and electronic transmission methods, is necessary for the brain to function and for neurons to stay healthy and not succumb to cognition loss diseases, such as Alzheimer's.

With this discovery, a number of small molecule compounds were found by ADispell to interact in the desired way prescribed by the invention and that can enhance cognition and neuron health. Another area that the lead compounds have therapeutic potential is treating toxicity and addiction to drugs of abuse. In addition, lead compounds can cause increased blood flow to the brain, a factor that can improve brain performance and health. Another finding by the company is that some of ADispell's lead compounds result in other beneficial behavior, such as an anti-anxiety effect

As ADispell has shown with in vivo studies that the treatment with the company's lead compounds result in noticeably improved cognition performance and with the anxiety state - the results sought with Alzheimer's and patients of other neurodegenerative disorders.

Proprietary rights to this technology are protected by a series of patents owned by ADispell.

Status of Technology

Three key molecules have been identified as having the characteristics of lead compounds. Each has properties that act per the ADispell mechanism and improve brain performance, thus allowing brain neurons to function more effectively and potentially halt the advancement of cognition loss.

The company has completed in vivo experiments with very exciting results. Animals impaired in a way similar to ADs and aged rats both showed significantly enhanced cognition performance. At the same time, the animals displayed reduced anxiety.

The company sees this as a platform technology with the potential to treat multiple diseases and conditions related to cognition loss, behavioral treatment, and drug addiction and toxicity.

This novel work is in the 'Lead Optimization' phase of the new drug discovery process and has significant in vivo results in hand. We now intend to move this exciting discovery to commercial availability.

We are happy to provide additional information about our technology. Please send a request to and let us know about your interest in the technology and our company.